Podcasts about anaplastic

Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10–15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. This podcast provides an overview of ALK-positive ALCL and IMT. The authors discuss the current treatment landscape, the role of ALK tyrosine kinase inhibitors, and areas of future research.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00275-6. All conflicts of interest can be found online. This podcast is intended for medical professionals.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Thyroid cancer is a complex disease with various subtypes and clinical presentations. While some cases can be successfully treated with standard therapy, others present challenges due to resistance to treatment and the development of aggressive forms of the disease. In a new research perspective, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer Center discuss the recent research that has shed light on the role of genetic alterations in mediating both resistance to BRAF inhibition and anaplastic transformation in thyroid cancer. On January 24, 2024, their paper was published in Oncotarget, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.” “An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.” Full blog - https://www.oncotarget.org/2024/02/08/genetic-alterations-in-thyroid-cancer-resistance-to-brafi-and-anaplastic-transformation/ DOI - https://doi.org/10.18632/oncotarget.28544 Correspondence to - Luc GT Morris - morrisl@mskcc.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28544 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, thyroid cancer, drug resistance, anaplastic transformation, BRAF inhibitors, PIK3CA About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957 Paper DOI -

BUFFALO, NY- January 29, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.” In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer Center discuss thyroid cancer. A subset of thyroid cancers present at advanced stage or with dedifferentiated histology and have limited response to standard therapy. Tumors harboring the BRAF V600E mutation may be treated with BRAF inhibitors; however, tumor response is often short-lived due to multiple compensatory resistance mechanisms. “One mode of resistance is the transition to an alternative cell state, which on rare occasions can correspond to tumor dedifferentiation.” DNA sequencing and RNA expression profiling show that thyroid tumors that dedifferentiate after BRAF inhibition are enriched in known genetic alterations that mediate resistance to BRAF blockade, and may also drive tumor dedifferentiation, including mutations in the PI3K/AKT/MTOR (PIK3CA, MTOR), MAP/ERK (MET, NF2, NRAS, RASA1), SWI/SNF chromatin remodeling complex (ARID2, PBRM1), and JAK/STAT pathways (JAK1). Given these findings, recent investigations have evaluated the efficacy of dual-target therapies; however, continued lack of long-term tumor control illustrates the complex and multifactorial nature of these compensatory mechanisms. Transition to an immune-suppressed state is another correlate of BRAF inhibitor resistance and tumor dedifferentiation, suggesting a possible role for concurrent targeted therapy with immunotherapy. “Investigations into combined targeted and immunotherapy are ongoing, but early results with checkpoint inhibitors, viral therapies, and CAR T-cells suggest enhanced anti-tumor immune activity with these combinations.” DOI - https://doi.org/10.18632/oncotarget.28544 Correspondence to - Luc GT Morris - morrisl@mskcc.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28544 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, thyroid cancer, drug resistance, anaplastic transformation, BRAF inhibitors, PIK3CA About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Kate Rice is proof of the power of persistence and positivity while navigating a cancer journey. Rice, an award-winning journalist, received a diagnosis of stage 4 anaplastic thyroid cancer in October 2021 — and quickly applied the same dogged dedication that had served her reporting in support of her own survival. “When I was a reporter, none of my sources or desired sources could escape me. Sooner or later, they were going to have to talk to me, I just have that kind of determination,” Rice said. “And it wasn't so much that I wanted to find out about the cancer I got diagnosed with; I wanted to find out who could cure it.” Years before receiving her thyroid cancer diagnosis, Rice had learned there were what doctors described as “indeterminant” nodules on her thyroid and was told to monitor them. She noticed small lumps on her neck in June 2021 and was told she would have to wait six months or so to be examined.  Rice, who had previously had a benign tumor removed from her neck and a case of melanoma, searched for doctors who could see her sooner — and, upon finally receiving her diagnosis, was told “I'll pray for you” by a surgeon. Anaplastic thyroid cancer, according to the American Thyroid Association, occurs in less than 2% of patients with thyroid cancers, but it is one of the fastest-growing and most aggressive of all cancers overall. The disease's average survival rate is six months, and just approximately one-fifth of patients live longer than a year after receiving a diagnosis. Immediately after receiving her diagnosis, Rice began sourcing for potential solutions, starting with a group text to her inner circle of loved ones. “My cousin, who had been one of the first people I'd sent (a message to when I) cast that wide net out to try to get information, had promptly gone online and found that (The University of Texas) MD Anderson Cancer Center in Houston had a clinic that specialized in this very rare (cancer) … and actually cured people with it. So, I got my diagnosis, I think, at two o'clock Friday afternoon, I was walking home up Columbus Avenue, I guess, and on the phone with MD Anderson, to get in there because I can jump on the phone with both feet.” Within days of receiving her diagnosis, Rice left New York City for Houston, Texas, seeking treatment from the Facilitating Anaplastic Thyroid Cancer Specialized Treatment Team at MD Anderson Cancer Center. Such determined self-advocacy, Rice said, is “absolutely essential.” “You have to stand up for yourself, you have to recognize that your doctors are specialists in whatever it is they're specialists in, but you're the specialist in your body,” she said. “And I knew something was going on. I mean, something was happening with my thyroid. Thyroid cancers, in general, are not the scariest cancers out there. They're serious cancers, and the treatment for a whole bunch of different thyroid cancers is not fun. But I knew this was something that was potentially a very big deal.  “And so when the first doctors I saw in New York were very relaxed and I couldn't get in to see a doctor I've been seeing for years because I had what are called indeterminate nodules on my thyroid — (which are) not malignant, but (they're) not benign, either — they were like, ‘Yeah, well, we can't get you in for six months, but that's OK,' I'm like, ‘No, not OK.' Even before I got the diagnosis, I was a pushy patient and we all have to do that. And the thing is, you're like, ‘Oh, I don't want to be much trouble. These guys are the pros, they know.' But really, you've got to listen to your body and stand up for yourself.” Following treatment at MD Anderson Cancer Center, Rice said she's “fine.” Now a radio disc jockey and ski instructor in Park City, Utah, she returns to Houston every six weeks for immunotherapy treatments at MD Anderson. She also documented her cancer journey in the 2023 book “Cured: A Tale of Badassery.” She has advice for fellow patients facing the long haul of a stage 4 cancer diagnosis. “Stay positive. Realize we all have to fight this cancer trauma that understandably, many people in this country, in this in the world, carry because we've seen terrible things happen to people we love, when my dad died of prostate cancer,” Rice said. “But, the thing to remember is so many cancers now are either curable or treatable and manageable. The whole thing is getting to the right place in time, which is a challenge with our healthcare system. But you really have to remember there is no such thing as false hope there is only hope.” For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

In January of 2022 14 year old high school freshman Mayah White was diagnosed with Stage 3 Anaplastic Large Cell Lymphoma after feeling exhausted since the previous October, and having lymph nodes pop up in her groin area. Mayah's mother Cailin will talk about the 134 day treatment that Mayah went through before she was told the great news that there was No Evidence Of Disease on June 22nd of last year. Thankfully that is still the case although Mayah still deals with side effects and after effects from her treatment. Cailin will also talk about their 501 C 3 Non Profit- Mayah's Militia which is hosting a Pickleball Tournament this Sunday September 17, as its first fundraiser as an official Non-Profit.

In the late summer of 2019 Molly Oldham had been suffering from migraines, vomiting, and feeling lethargic, but she was still planning on leaving for her Freshman year at the University of North Carolina Greensboro where she was to study Musical Theatre. Unfortunately she was diagnosed with Anaplastic Emendymoma which is a form of Brain Cancer. Since her diagnosis, Molly has had 3 brain surgeries , many radiation treatments, and has suffered from side effects including Grand Mal Seizures. Molly however continues to live her best possible as she has sung the National Anthem twice at at Florida Panthers Hockey Games, performed as a professional in a play, and had her inspiring story told on the View. Molly has also found time to advocate for others in the cause of AYA or Adolescent and Young Adult Cancer. 

Joseph Scharpf, MD, FACS, Director of Head and Neck Endocrine Surgery at the Cleveland Clinic Head and Neck Institute, and Emrullah Yilmaz, MD, PhD, an oncologist at Cleveland Clinic Taussig Cancer Institute, specializing in head and neck cancers, join the Cancer Advances podcast to discuss their study that provides insights to treatment strategies and tumor characteristics of anaplastic thyroid cancer. Listen as Dr. Scharpf and Dr. Yilmaz discuss patients with BRAF mutations and Cleveland Clinic's collaborative approach for thyroid cancer care.

Breast implant-associated anaplastic large cell lymphoma, also called BIA-ALCL, is a rare type of cancer of the immune system that can develop in the scar tissue capsule and fluid surrounding a breast implant. In some cases, it can spread throughout the body. BIA-ALCL is curable in most patients if it's diagnosed early and treated appropriately, but a small number of women have died from the illness. Listen to the episode to hear Dr. Zafar explain: what we currently know about BIA-ALCL and its causes treatments for BIA-ALCL the differences between the three types of capsulectomies available reconstruction options for women who have implants removed

Interview with Joseph Scharpf, MD, author of Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience. Hosted by Paul C. Bryson, MD, MBA.

Interview with Joseph Scharpf, MD, author of Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience. Hosted by Paul C. Bryson, MD, MBA.

Being a front-line worker at the start of the Coronavirus pandemic is hard enough. What happens when you go from front-line work to patient? Episode 3 hears the story of Ian Youngblood, a 29 year-old nurse sent to NYC as COVID-19 started to ravage our country. He quickly went from treating others to being treated, but not for COVID, for a grade 3 Anaplastic oligodendroglioma--brain cancer. Three years later, Ian talks about that day, and how he sees the world now.   Season Sponsor: Gamma Tile Therapy (GT Medical Technologies)   Episode Sponsors: Highmark BCBS of WNY, OncoSynergy Inc. **Music credits to Ronald Lynn Dickison for their song "Mourning"  

After experiencing blinding headaches in early August of 2021, Shawn Mahoney's 6 year old  daughter Layla was diagnosed with a High Grade Anaplastic Supertentorial Ependymoma, which is a form of Pediatric Brain Cancer. After her initial surgery on August 2nd of last year Layla had to undergo another surgery just 5 weeks later, followed by 33 rounds of proton therapy, followed by another surgery on March 11th of this year, which finally completely removed her tumor. On May 18th, DNA/RNA sequencing showed that there was an 81.82 chance that her cancer would NOT come back and Layla was able to complete her academic year in school. There have been new developments in her case since this podcast was recorded and they will be talked about on my Outtro. 

Michelle Lambert was diagnosed with stage 4 Anaplastic thyroid cancer in 2018. Initially, she felt a pain in her right ear and found a small lump right above her collar bone. Ultrasounds and biopsy tests detected thyroid cancer. She went through 8 rounds of chemotherapy with radiation therapies which went for six months. She did meditation, kept positive people around her and followed a proper diet plan that helped her recover faster. She tells everyone not to give up, and even if things are falling apart, hang on to the rope, and things will get better. Summing up her journey, she says, " You never know when is your last day, but coming close to death, you get to see all the things you did in your lifetime, so value all the little things". Zenonco.io - Making quality integrative oncology cancer care accessible to all. Visit our website: https://zenonco.io/ If you or your loved one has been diagnosed with cancer recently, and need guidance on treatment or have any doubts or queries, please call ZenOnco.io on +91 99 30 70 90 00.

The identification of an actionable gene mutation or translocation in patients with cancer can give researchers a target for new drug therapies. One such mutation, found in some patients with non-small cell lung cancer (NSCLC), is anaplastic lymphoma kinase (ALK) gene rearrangement. However, the exact population of patients that present with ALK rearrangement has not been fully characterized. Identifying the subpopulation of patients who present with ALK rearrangement may lead to better overall treatment outcomes. Researchers—from University of Mississippi Medical Center, Roche Information Solutions, Roche Diagnostics Corporation, Genesis Research, and Houston Methodist Hospital—conducted a retrospective study of nearly 20,000 patients with advanced NSCLC (aNSCLC). The researchers assessed ALK rearrangement prevalence in the cohort overall and then categorized the data using patient characteristics. Their paper was published on the cover of Oncotarget's Volume 12, Issue 23, and entitled, “Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States – retrospective real world data”. “We performed a retrospective study of a database to acquire real-world clinical data on the frequency of the translocation in a large pool of patients drawn primarily from community hospitals and practices.” Full blog - https://www.oncotarget.org/2021/11/10/new-study-alk-rearrangement-among-lung-cancer-patients/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28114 DOI - https://doi.org/10.18632/oncotarget.28114 Full text - https://www.oncotarget.com/article/28114/text/ Correspondence to - Eric H. Bernicker - bernicker@houstonmethodist.org Keywords - ALK rearrangement, NSCLC, prevalence About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

To claim CME credit, visit https://i3health.com/oda-thyroid While thyroid cancer is the most common endocrine cancer, prognosis and survival rates vary widely by subtype. This episode of Oncology Data Advisor will focus on advances in the management of differentiated and anaplastic thyroid cancers. It features perspectives from two noted experts in the field: Dr. Jochen Lorch, Director of the Thyroid Cancer Center at Dana-Farber Cancer Institute; and Ms. Carolyn Grande, Oncology Nurse Practitioner at Abramson Cancer Center. This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. Free CME and NCPD credit are available for this podcast. To claim credit and obtain further information, including faculty disclosures, visit i3Health.com/ODA-thyroid.

This weeks episode reads like a Lifetime Movie! It has twists, it has turns, it has cancer. Today you are meeting Kayla, she is a Brain Tumor (Anaplastic Ganglioglioma/Glioblastoma Multiform ) survivor. Her journey through her initial symptoms, diagnosis, treatment and life after is so incredible. She was a joy to get to know, and you will LOVE LOVE LOVE her Cancer Story. You can find Kayla: IG: @kmhendri10 FB: https://www.facebook.com/kayla.hendrickson.9 --- Support this podcast: https://anchor.fm/mycancerstorypodcast/support

Expert: Nicola Rocco, University of Naples Federico II, Naples, Italy Questions: 1- What is Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)? 2- What is the clinical presentation of BIA-ALCL? 3- How can I diagnose BIA-ALCL? 4- How can I stage BIA-ALCL? 5- What is the treatment for BIA-ALCL?

Haley, a junior at North Dakota State University, in Fargo North Dakota, is pursuing a Bachelor's Degree in Accounting with intentions of obtaining a CPA license. Haley has hopes of becoming a forensic accountant with the FBI one day. Born and raised in Brainerd, Minnesota Haley learned her love for community and volunteering. She has been active in her community and has logged thousands of volunteer hours over the last several years and was even named Brainerd’s Youth Volunteer in 2018. Competing in the United States National Pageant system for 5 years she has volunteered as Miss Teen Midwest, Miss Teen Baxter, Miss Teen Gull Lake, and Miss Teen Minnesota. She loves the United States system because of the dedication to service they stand for. Hearing that someone in your family has cancer, especially a child, can be hard even for a 14-year-old. Haley’s cousin was  7 years old and diagnosed with terminal brain cancer called Anaplastic astrocytoma grade III (AA3) in 2014. Allison, Haley’s cousin, taught many so much. She had a heart of gold, she was loving, caring, funny, and out-spoken. At the end of her life she still never complained about why she can't do what other kids could. That just shows how strong and brave she was. Ally's cancer turned into a glioblastoma, the worst kind, in over a 6 week period. She lost her battle on December 10th, 2016. Haley became passionate about advocating for childhood cancer awareness when her cousin was first diagnosed. She started Ally’s Wings, a 501(c) 3 non-profit, that brings awareness to the lack of national research funding in the US for all childhood cancers. Ally’s Wings also makes tie blankets/care packages for kids battling cancer. Haley has a goal to deliver a blanket to all 50 states! As Miss Teen United States Haley is excited to bring awareness to childhood cancer.FB @teenunitedstatesIG @officialteenunitedstatesand @AllysWingsSupport the show (https://podcasts.apple.com/us/podcast/beauty-call-podcast/id1462542236)

Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test.

Tune in to listen to Roxanne Vermeland inspiring story with BIA-ALCL --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

More than 700 people worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The U.S. Food and Drug Administration (FDA) believes that women with textured breast implants have a small but increased risk of developing this uncommon cancer. In this episode, Mark Clemens, M.D., plastic surgeon at The University of Texas MD Anderson Cancer Center and one of the world's leading experts, discusses BIA-ALCL treatment and prophylactic removal of breast implants. The information and material provided during this podcast are just recommendations. There are other medically appropriate options available that are not addressed in this podcast, and every provider must exercise independent medical judgment to determine what is medically appropriate and best practice based on each individual patient's medical needs. As a listener of this podcast, you agree to release from liability and hold harmless UT MD Anderson, its agencies, officers, and employees for any accident, injury, illness, death, loss, or damage arising from or relating to, directly or indirectly, this podcast.

 HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Samantha Reiss details the standard care for glioblastoma, the most aggressive form of brain tumors. She highlights main considerations surrounding the use of temozolomide, TTFs, and bevacizumab, and touches on the more controversial topics of treating elderly patients and retreatment care options for recurrent glioblastoma. She concludes with an overview of anaplastic gliomas in patients who harbor the 1P19q codeletion and those who don’t.   In this episode you will learn:   Central Nervous System Malignancies: Top 10 Clinical Pearls Standard of care for glioblastoma, the most aggressive form of brain tumors Considerations when determining if temozolomide is an absolute standard of care for patients with MGMT unmethylated tumors Supportive care for the upfront treatment of glioblastoma and options for PJP prophylaxis The role of the medical device tumor treating fields (TTF) in the upfront treatment of glioblastomas Controversial talking points regarding the treatment of glioblastomas in elderly patients The role of bevacizumab as a treatment of glioblastoma and toxicities to monitor for Recurrent glioblastoma considerations and retreatment care options Goals for the treatment of low-grade gliomas and the role of chemotherapy in this setting Anaplastic gliomas in patients who harbor the 1P19q codeletion and those who don’t   Mentioned in This Episode: HOPA   Quotes:   “This trial showed an overall improvement in survival from 12.1 months with radiation alone compared to 14.6 months with radiation plus temozolomide and the survival benefit lasted through the five-year follow-up.” — Dr. Samantha Reiss   “Chemotherapy-induced nausea and vomiting from temozolomide therapy is dose-dependent and standard emetic prophylaxis should be considered for all patients.” — Dr. Samantha Reiss   “The addition of tumor treating fields improved progression free-survival and overall survival in this patient population.” — Dr. Samantha Reiss   “Timing of radiation therapy should be considered to speed the progression and possibility of late neurotoxicity that patients can experience after brain radiation.” — Dr. Samantha Reiss  

Jeffrey Klein, MD, reviews the article, “Breast Implant–associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms.” See Sharma, et al, RadioGraphics 2020; 40:609–628. Read Full Text: https://pubs.rsna.org/doi/full/10.1148/rg.2020190198

Join us this week as Dr. Daniel Barrett speaks about important issues with fellow board certified plastic surgeon, Dr. Ritu Chopra.  You'll hear about the latest news and evidence regarding Breast Implant Associated Illness (BIAI) and Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)   Learn the facts regarding breast implants and how to navigate the dangers.  The lines are becoming blurred between accurate information regarding what constitutes real danger, versus widespread myths. This episode focuses on delivering the correct information and the importance of being informed by board certified plastic surgeons vs. random voices of the internet.    Dr. Ritu Chopra also shares the importance of informed consent and the difference between good and bad sources of information.  This episode is entertaining and extremely informative even diving into subjects like the gut biome.  Don't miss this one!   Check out this episode and more on our Youtube channel and be sure to subscribe, comment, and click the notifications bell for our latest!  Visit our website at www.drdanielbarrett.com for more information.  

This is a story of a Angelica Warren. At 19 she went to the ER and, after a series of tests, was told she wasn't going to make it through the night. Cancer, surgeries, chemo, seizures, her story is truly amazing and is sure to inspire you. Join us as Angelica describes how when she was at her weakest (90lbs) Cannabis helped her regain the strength to fight back.

Dr van den Bent talks to ecancertv at ASCO 2016 about the early results from a European phase III trial which looked at the use of adjuvant temozolomide in anaplastic glioma. It was found that anaplastic glioma patients without 1p/19q co-deletion benefited from this. The addition of adjuvant temozolomide also delayed disease progression by more than two years.

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

The prognostic importance of ALK-protein expression was established over a decade ago. More recent studies emphasize that age is also an important driving force and in patients